|
**Overview**: ENA ANA Quantitative Panel**Introduction**: The ENA ANA Quantitative Panel is a diagnostic tool designed to screen for autoimmune disorders using serum samples. In India, systemic autoimmune diseases (SLE, Sjogren's, scleroderma, mixed CTD) affect ~0.5-1 percent of the population, predominantly women, with extractable nuclear antigens (ENA) including anti-Ro, anti-La, anti-Smith, anti-RNP, anti-Scl-70, anti-Jo-1, anti-centromere providing disease-specific diagnosis. High morbidity from underdiagnosis in rural/low-SES women, limited rheumatology access, delayed immunosuppression leading to organ damage (renal, pulmonary). Per immunology practices aligned with ICMR and Indian Rheumatology Association guidelines, the test employs immunoassay for quantitative ENA/ANA over 1-2 days with high specificity, valuable for confirming CTD and guiding therapy. This diagnostic falls under autoimmune screening and targets patients with joint pain, rash, Raynaud's, or organ symptoms, addressing accurate detection to guide treatment and prognosis. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling precise identification and reducing complications. Its serum-based approach ensures reliable antibody quantification.**Other Names**: ENA ANA Pnl.**FDA Status**: FDA approved, CLIA certified for immunology, compliant with 2025 standards.**Historical Milestone**: ENA panel expanded; in India, used in rheumatology clinics.**Purpose**: The test assesses 7 parameters including anti-Ro to guide autoimmune disorder screening, detect specific antibodies, inform management.**Test Parameters**: 1. Anti-Ro, 2. Anti-La, 3. Anti-Smith, 4. Anti-RNP, 5. Anti-Scl-70, 6. Anti-Jo-1, 7. Anti-Centromere.**Pretest Condition**: No fasting required; patients should report joint pain, rash, or organ symptoms.**Specimen**: 3 mL serum in 1 SST, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 8 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.**Medical History**: Patients should provide details on symptoms, organ involvement, family autoimmune history.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of untreated autoimmune disorders including organ damage, benefits of early detection, and minimal discomfort from venipuncture.**Procedural Considerations**: The test involves sample processing using immunoassay by trained personnel to ensure sterile technique, avoid hemolysis, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, hemolysis, or concurrent infections can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Positive specific antibodies indicate CTD, necessitating specialist input. Negative may require follow-up if symptoms persist.**Specialist Consultation**: Rheumatologists should be consulted for management.**Additional Supporting Tests**: ANA pattern, complement levels for confirmation.**Test Limitations**: May miss rare antibodies; comprehensive approach required.**References**: Indian Journal of Rheumatology 2024, Autoimmune Studies India 2023. |
